Herceptin Biosimilar Market by Product Type and Application - Global Industry Analysis & Forecast to 2027
Published On : October 2019 Pages : 170 Category: Pharma & Healthcare Report Code : HC106319
Herceptin Biosimilar Market by Product Type (Tablet, Capsule, Others) Application (Healthcare And Pharmaceuticals, Others) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The herceptin biosimilar market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Herceptin is the cancer medication utilized in the treatment of the breast cancer. It is monoclonal antibodies and are utilized alongside the chemotherapy drugs. It is likewise named as atargeted therapy drug. Trastuzumab is the one of the brand name herceptin which is directed by moderate infusion to a vein.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global herceptin biosimilar market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Mylan
- Gedeon Richter
- Amgen
- Celltrion
- Genor Biopharma
- Mabion
- The Instituto Vital Brazil
- AryoGen Biopharma
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Herceptin Biosimilar Market , By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Tablet
o Capsule
o Others
· Herceptin Biosimilar Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Healthcare And Pharmaceuticals
o Others
· Herceptin Biosimilar Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Mylan
o Gedeon Richter
o Amgen
o Celltrion
o Genor Biopharma
o Mabion
o The Instituto Vital Brazil
o AryoGen Biopharma
· Herceptin Biosimilar Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Herceptin Biosimilar Market , By Country
o U.S. Herceptin Biosimilar Market
o Canada Herceptin Biosimilar Market
o Mexico Herceptin Biosimilar Market
o Europe
§ Europe Herceptin Biosimilar Market , By Country
· Germany Herceptin Biosimilar Market
o UK Herceptin Biosimilar Market
o France Herceptin Biosimilar Market
o Russia Herceptin Biosimilar Market
o Italy Herceptin Biosimilar Market
o Rest of Europe Herceptin Biosimilar Market
o Asia-Pacific
§ Asia-Pacific Herceptin Biosimilar Market , By Country
o China Herceptin Biosimilar Market
o Japan Herceptin Biosimilar Market
o South Korea Herceptin Biosimilar Market
o India Herceptin Biosimilar Market
o Southeast Asia Herceptin Biosimilar Market
o Rest of Asia-Pacific Herceptin Biosimilar Market
o South America
§ South America Herceptin Biosimilar Market
o Brazil Herceptin Biosimilar Market
o Argentina Herceptin Biosimilar Market
o Columbia Herceptin Biosimilar Market
o Rest of South America Herceptin Biosimilar Market
o Middle East and Africa
§ Middle East and Africa Herceptin Biosimilar Market
o Saudi Arabia Herceptin Biosimilar Market
o UAE Herceptin Biosimilar Market
o Egypt Herceptin Biosimilar Market
o Nigeria Herceptin Biosimilar Market
o South Africa Herceptin Biosimilar Market
o Rest of MEA Herceptin Biosimilar Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Herceptin Biosimilar Market, By Product Type
5.1. Introduction
5.2. Global Herceptin Biosimilar Revenue and Market Share by Product Type (2017-2027)
5.2.1. Global Herceptin Biosimilar Revenue and Revenue Share by Product Type (2017-2027)
5.3. Tablet
5.3.1. Global Tablet Revenue and Growth Rate (2017-2027)
5.4. Capsule
5.4.1. Global Capsule Revenue and Growth Rate (2017-2027)
5.5. Others
5.5.1. Global Others Revenue and Growth Rate (2017-2027)
6. Herceptin Biosimilar Market, By Application
6.1. Introduction
6.2. Global Herceptin Biosimilar Revenue and Market Share by Application (2017-2027)
6.2.1. Global Herceptin Biosimilar Revenue and Revenue Share by Application (2017-2027)
6.3. Healthcare And Pharmaceuticals
6.3.1. Global Healthcare And Pharmaceuticals Revenue and Growth Rate (2017-2027)
6.4. Others
6.4.1. Global Others Revenue and Growth Rate (2017-2027)
7. Herceptin Biosimilar Market, By Region
7.1. Introduction
7.2. Global Herceptin Biosimilar Revenue and Market Share by Regions
7.2.1. Global Herceptin Biosimilar Revenue by Regions (2017-2027)
7.3. North America Herceptin Biosimilar by Countries
7.3.1. North America Herceptin Biosimilar Revenue and Growth Rate (2017-2027)
7.3.2. North America Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Herceptin Biosimilar by Countries
7.4.1. Europe Herceptin Biosimilar Revenue and Growth Rate (2017-2027)
7.4.2. Europe Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Herceptin Biosimilar by Countries
7.5.1. Asia-Pacific Herceptin Biosimilar Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Herceptin Biosimilar by Countries
7.6.1. South America Herceptin Biosimilar Revenue and Growth Rate (2017-2027)
7.6.2. South America Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Herceptin Biosimilar by Countries
7.7.1. Middle East and Africa Herceptin Biosimilar Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Mylan
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Gedeon Richter
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Amgen
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Celltrion
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Genor Biopharma
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Mabion
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. The Instituto Vital Brazil
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. AryoGen Biopharma
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
9. Herceptin Biosimilar Market Forecast (2017-2027)
9.1. Global Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Herceptin Biosimilar Market Forecast by Regions (2017-2027)
9.2.1. North America Herceptin Biosimilar Market Forecast (2017-2027)
9.2.1.1. United States Herceptin Biosimilar Market Forecast (2017-2027)
9.2.1.2. Canada Herceptin Biosimilar Market Forecast (2017-2027)
9.2.1.3. Mexico Herceptin Biosimilar Market Forecast (2017-2027)
9.2.2. Europe Herceptin Biosimilar Market Forecast (2017-2027)
9.2.2.1. Germany Herceptin Biosimilar Market Forecast (2017-2027)
9.2.2.2. France Herceptin Biosimilar Market Forecast (2017-2027)
9.2.2.3. UK Herceptin Biosimilar Market Forecast (2017-2027)
9.2.2.4. Russia Herceptin Biosimilar Market Forecast (2017-2027)
9.2.2.5. Italy Herceptin Biosimilar Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Herceptin Biosimilar Market Forecast (2017-2027)
9.2.3. Asia-Pacific Herceptin Biosimilar Market Forecast (2017-2027)
9.2.3.1. China Herceptin Biosimilar Market Forecast (2017-2027)
9.2.3.2. Japan Herceptin Biosimilar Market Forecast (2017-2027)
9.2.3.3. Korea Herceptin Biosimilar Market Forecast (2017-2027)
9.2.3.4. India Herceptin Biosimilar Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Herceptin Biosimilar Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Herceptin Biosimilar Market Forecast (2017-2027)
9.2.4. South America Herceptin Biosimilar Market Forecast (2017-2027)
9.2.4.1. Brazil Herceptin Biosimilar Market Forecast (2017-2027)
9.2.4.2. Argentina Herceptin Biosimilar Market Forecast (2017-2027)
9.2.4.3. Columbia Herceptin Biosimilar Market Forecast (2017-2027)
9.2.4.4. Rest of South America Herceptin Biosimilar Market Forecast (2017-2027)
9.2.5. Middle East and Africa Herceptin Biosimilar Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Herceptin Biosimilar Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Herceptin Biosimilar Market Forecast (2017-2027)
9.2.5.3. Egypt Herceptin Biosimilar Market Forecast (2017-2027)
9.2.5.4. Nigeria Herceptin Biosimilar Market Forecast (2017-2027)
9.2.5.5. South Africa Herceptin Biosimilar Market Forecast (2017-2027)
9.2.5.6. Turkey Herceptin Biosimilar Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Herceptin Biosimilar Market Forecast (2017-2027)
9.3. Herceptin Biosimilar Market Forecast by Product Type (2017-2027)
9.3.1. Herceptin Biosimilar Forecast by Product Type (2017-2027)
9.3.2. Herceptin Biosimilar Market Share Forecast by Product Type (2017-2027)
9.4. Herceptin Biosimilar Market Forecast by Application (2017-2027)
9.4.1. Herceptin Biosimilar Forecast by Application (2017-2027)
9.4.2. Herceptin Biosimilar Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Herceptin Biosimilar Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Herceptin Biosimilar Revenue and Revenue Share by Product Type (2017-2018)
Figure Global Tablet Revenue and Growth Rate (2017-2018)
Figure Global Capsule Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Herceptin Biosimilar Revenue and Revenue Share by Application (2017-2018)
Figure Global Healthcare And Pharmaceuticals Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Herceptin Biosimilar Revenue by Regions (2017-2018)
Figure North America Herceptin Biosimilar Growth Rate (2017-2018)
Figure North America Herceptin Biosimilar Revenue and Growth Rate (2017-2018)
Figure North America Herceptin Biosimilar by Countries (2017-2018)
Figure North America Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2018)
Figure United States Herceptin Biosimilar Growth Rate (2017-2018)
Figure United States Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Herceptin Biosimilar Growth Rate (2017-2018)
Figure Canada Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Herceptin Biosimilar Growth Rate (2017-2018)
Figure Mexico Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Herceptin Biosimilar Growth Rate (2017-2018)
Figure Europe Herceptin Biosimilar Revenue and Growth Rate (2017-2018)
Figure Europe Herceptin Biosimilar by Countries (2017-2018)
Figure Europe Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2018)
Figure Germany Herceptin Biosimilar Growth Rate (2017-2018)
Figure Germany Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Herceptin Biosimilar Growth Rate (2017-2018)
Figure France Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Herceptin Biosimilar Growth Rate (2017-2018)
Figure UK Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Herceptin Biosimilar Growth Rate (2017-2018)
Figure Russia Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Herceptin Biosimilar Growth Rate (2017-2018)
Figure Italy Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Herceptin Biosimilar Growth Rate (2017-2018)
Figure Rest of Europe Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Herceptin Biosimilar Growth Rate (2017-2018)
Figure Asia-Pacific Herceptin Biosimilar Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Herceptin Biosimilar by Countries (2017-2018)
Figure Asia-Pacific Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2018)
Figure China Herceptin Biosimilar Growth Rate (2017-2018)
Figure China Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Herceptin Biosimilar Growth Rate (2017-2018)
Figure Japan Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Herceptin Biosimilar Growth Rate (2017-2018)
Figure Korea Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Herceptin Biosimilar Growth Rate (2017-2018)
Figure India Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Herceptin Biosimilar Growth Rate (2017-2018)
Figure Southeast Asia Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Herceptin Biosimilar Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Herceptin Biosimilar Growth Rate (2017-2018)
Figure South America Herceptin Biosimilar Revenue and Growth Rate (2017-2018)
Figure South America Herceptin Biosimilar by Countries (2017-2018)
Figure South America Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Herceptin Biosimilar Growth Rate (2017-2018)
Figure Brazil Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Herceptin Biosimilar Growth Rate (2017-2018)
Figure Argentina Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Herceptin Biosimilar Growth Rate (2017-2018)
Figure Columbia Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Herceptin Biosimilar Growth Rate (2017-2018)
Figure Rest of South America Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Herceptin Biosimilar Growth Rate (2017-2018)
Figure Middle East and Africa Herceptin Biosimilar Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Herceptin Biosimilar by Countries (2017-2018)
Figure Middle East and Africa Herceptin Biosimilar Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Herceptin Biosimilar Growth Rate (2017-2018)
Figure Saudi Arabia Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Herceptin Biosimilar Growth Rate (2017-2018)
Figure United Arab Emirates Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Herceptin Biosimilar Growth Rate (2017-2018)
Figure Egypt Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Herceptin Biosimilar Growth Rate (2017-2018)
Figure Nigeria Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Herceptin Biosimilar Growth Rate (2017-2018)
Figure South Africa Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Herceptin Biosimilar Growth Rate (2017-2018)
Figure Turkey Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Herceptin Biosimilar Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2017-2018)
Table Mylan Herceptin Biosimilar Financial Overview
Table Gedeon Richter Herceptin Biosimilar Financial Overview
Table Amgen Herceptin Biosimilar Financial Overview
Table Celltrion Herceptin Biosimilar Financial Overview
Table Genor Biopharma Herceptin Biosimilar Financial Overview
Table Mabion Herceptin Biosimilar Financial Overview
Table The Instituto Vital Brazil Herceptin Biosimilar Financial Overview
Table AryoGen Biopharma Herceptin Biosimilar Financial Overview
Figure Global Herceptin Biosimilar Revenue (Millions USD) and Growth Rate (2018-2025)
Table Herceptin Biosimilar Market Forecast by Regions (2018-2025)
Figure North America Herceptin Biosimilar Market Forecast (2018-2025)
Figure United States Herceptin Biosimilar Market Forecast (2018-2025)
Figure Canada Herceptin Biosimilar Market Forecast (2018-2025)
Figure Mexico Herceptin Biosimilar Market Forecast (2018-2025)
Figure Europe Herceptin Biosimilar Market Forecast (2018-2025)
Figure Germany Herceptin Biosimilar Market Forecast (2018-2025)
Figure France Herceptin Biosimilar Market Forecast (2018-2025)
Figure UK Herceptin Biosimilar Market Forecast (2018-2025)
Figure Russia Herceptin Biosimilar Market Forecast (2018-2025)
Figure Italy Herceptin Biosimilar Market Forecast (2018-2025)
Figure Rest of Europe Herceptin Biosimilar Market Forecast (2018-2025)
Figure Asia-Pacific Herceptin Biosimilar Market Forecast (2018-2025)
Figure China Herceptin Biosimilar Market Forecast (2018-2025)
Figure Japan Herceptin Biosimilar Market Forecast (2018-2025)
Figure Korea Herceptin Biosimilar Market Forecast (2018-2025)
Figure India Herceptin Biosimilar Market Forecast (2018-2025)
Figure Southeast Asia Herceptin Biosimilar Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Herceptin Biosimilar Market Forecast (2018-2025)
Figure South America Herceptin Biosimilar Market Forecast (2018-2025)
Figure Brazil Herceptin Biosimilar Market Forecast (2018-2025)
Figure Argentina Herceptin Biosimilar Market Forecast (2018-2025)
Figure Columbia Herceptin Biosimilar Market Forecast (2018-2025)
Figure Rest of South America Herceptin Biosimilar Market Forecast (2018-2025)
Figure Middle East and Africa Herceptin Biosimilar Market Forecast (2018-2025)
Figure Saudi Arabia Herceptin Biosimilar Market Forecast (2018-2025)
Figure United Arab Emirates Herceptin Biosimilar Market Forecast (2018-2025)
Figure Egypt Herceptin Biosimilar Market Forecast (2018-2025)
Figure Nigeria Herceptin Biosimilar Market Forecast (2018-2025)
Figure South Africa Herceptin Biosimilar Market Forecast (2018-2025)
Figure Turkey Herceptin Biosimilar Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Herceptin Biosimilar Market Forecast (2018-2025)
Figure Global Herceptin Biosimilar Forecast by Product Type (2018-2025)
Figure Global Herceptin Biosimilar Market Share Forecast by Product Type (2018-2025)
Figure Global Herceptin Biosimilar Forecast by Product Type (2018-2025)
Figure Global Herceptin Biosimilar Forecast by Application (2018-2025)
Figure Global Herceptin Biosimilar Market Share Forecast by Application (2018-2025)
Figure Global Herceptin Biosimilar Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|